In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids

Detalhes bibliográficos
Autor(a) principal: Boccato Payolla, Filipe
Data de Publicação: 2020
Outros Autores: Andrade Aleixo, Nadia, Resende Nogueira, Flávia Aparecida, Massabni, Antonio Carlos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
DOI: 10.32635/2176-9745.RBC.2020v66n1.649
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/649
Resumo: Introduction: Three vanadium complexes with orotic and glutamic acids, in their anion forms, were prepared and their in vitro cytotoxicity toward human lung fibroblasts (MRC-5), human hepatocellular carcinoma (HepG2) and human colorectal adenocarcinoma (Caco-2) are reported. Objective: Describe the synthesis and characterization of new vanadium complexes with orotic and glutamic acids, and test its antitumor activity against HepG2 and Caco-2. Method: The complexes were formulated as VO (oro), VO (α-glu) and VO (γ-glu) based on chemical, thermogravimetric analyses and infrared spectra. Results: Resazurin assay demonstrates its cytotoxicity against the HepG2 and Caco-2 cell lines with the IC50 ranging from 7.90 to 44.56 μmol.L-1. The cytotoxicity profiles indicate that the tumoral lines show more activity than the cells MRC-5, with selectivity indexes ranging from 1.58 to 8.96. Conclusion: The three complexes had better in vitro activity than cisplatin for both normal and cancer cell lines. The IC50 values are two to six times better for the cancer cell lines and five to seven times better for the normal cell lines. This study indicates that the complexes obtained are promising candidates for antitumor drugs.
id INCA-1_b3b58b3e3fce767b22e35341bb7966a5
oai_identifier_str oai:rbc.inca.gov.br:article/649
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
spelling In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic AcidsEstudios in vitro de la Actividad Antitumoral de Complejos de Vanadio con Ácidos Orótico y GlutámicoEstudos in vitro da Atividade Antitumoral de Complexos de Vanádio com Ácidos Órotico e GlutâmicoCarcinoma HepatocelularCompostos de VanádioEnsaios de Seleção de Medicamentos AntitumoraisCarcinoma, HepatocellularVanadium CompoundsDrug Screening Assays, AntitumorCarcinoma HepatocelularCompuestos de VanadioEnsayos de Selección de Medicamentos AntitumoralesIntroduction: Three vanadium complexes with orotic and glutamic acids, in their anion forms, were prepared and their in vitro cytotoxicity toward human lung fibroblasts (MRC-5), human hepatocellular carcinoma (HepG2) and human colorectal adenocarcinoma (Caco-2) are reported. Objective: Describe the synthesis and characterization of new vanadium complexes with orotic and glutamic acids, and test its antitumor activity against HepG2 and Caco-2. Method: The complexes were formulated as VO (oro), VO (α-glu) and VO (γ-glu) based on chemical, thermogravimetric analyses and infrared spectra. Results: Resazurin assay demonstrates its cytotoxicity against the HepG2 and Caco-2 cell lines with the IC50 ranging from 7.90 to 44.56 μmol.L-1. The cytotoxicity profiles indicate that the tumoral lines show more activity than the cells MRC-5, with selectivity indexes ranging from 1.58 to 8.96. Conclusion: The three complexes had better in vitro activity than cisplatin for both normal and cancer cell lines. The IC50 values are two to six times better for the cancer cell lines and five to seven times better for the normal cell lines. This study indicates that the complexes obtained are promising candidates for antitumor drugs.Introducción: Tres complejos de vanadio con ácidos orótico y glutámico, en sus formas aniónicas, fueram preparados. Su citotoxicidad in vitro hacia los fibroblastos pulmonares humanos (MRC-5), el carcinoma hepatocelular humano (HepG2) y el adenocarcinoma colorrectal humano (Caco-2) son reportados. Objetivo: Los principales objetivos de este trabajo son describir la síntesis y caracterización de nuevos complejos de vanadio con ácidos orótico y glutámico y probar su actividad antitumoral contra el HepG2 y el Caco-2. Método: Los complejos fueron formulados como VO (oro), VO (α-glu) y VO (γ-glu) basados en análisis químicos, termogravimétricos y espectros infrarrojos. El ensayo de resazurina demuestra su citotoxicidad contra las líneas celulares HepG2 y Caco-2 con el IC50 que van de 7,90 a 44,56 μmol.L-1. Los perfiles de citotoxicidad indican que las líneas tumorales presentan mayor actividad que los MRC-5, con índices de selectividad que van de 1,58 a 8,96. Conclusión: Los tres complejos tuvieron mejor actividad in vitro que el cisplatino, tanto para líneas celulares normales como para líneas celulares cancerosas. Los valores del IC50 son de dos a seis veces mejores para las líneas celulares de cáncer y de cinco a siete veces mejores para las líneas celulares normales. Este estudio indica que los complejos obtenidos son candidatos prometedores para fármacos antitumorales.Introdução: Foram preparados três complexos de vanádio com ácidos orótico e glutâmico, em suas formas aniônicas, e foi testada sua citotoxicidade in vitro para fibroblastos pulmonares humanos (MRC-5), carcinoma hepatocelular humano (HepG2) e adenocarcinoma colorretal humano (Caco-2). Objetivo: Descrever a síntese e caracterização de novos complexos de vanádio com ácidos orótico e glutâmico e testar sua atividade antitumoral contra HepG2 e Caco-2. Método: Os complexos foram formulados como VO (oro), VO (α-glu) e VO (γ-glu) com base em análises químicas, termogravimétricas e espectros no infravermelho. Resultados: O ensaio de resazurina demonstrou sua citotoxicidade contra as linhagens celulares HepG2 e Caco-2 com o IC50 variando de 7,90 a 44,56 μmol.L-1. Os perfis de citotoxicidade indicam que as linhas tumorais apresentam maior atividade que as células MRC-5, com índices de seletividade variando de 1,58 a 8,96. Conclusão: Os três complexos tiveram melhor atividade in vitro do que a cisplatina, tanto para linhagens celulares normais como cancerosas. Os valores de IC50 são de duas a seis vezes melhores para as linhagens celulares cancerosas e de cinco a sete vezes melhores para as linhagens celulares normais. Este estudo indica que os complexos obtidos são promissores candidatos a fármacos antitumorais.INCA2020-01-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/64910.32635/2176-9745.RBC.2020v66n1.649Revista Brasileira de Cancerologia; Vol. 66 No. 1 (2020): Jan./Feb./Mar.; e-04649Revista Brasileira de Cancerologia; Vol. 66 Núm. 1 (2020): enero/feb./marzo; e-04649Revista Brasileira de Cancerologia; v. 66 n. 1 (2020): jan./fev.mar.; e-046492176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAenghttps://rbc.inca.gov.br/index.php/revista/article/view/649/533Copyright (c) 2020 Revista Brasileira de Cancerologiahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBoccato Payolla, FilipeAndrade Aleixo, NadiaResende Nogueira, Flávia AparecidaMassabni, Antonio Carlos2023-04-20T18:11:29Zoai:rbc.inca.gov.br:article/649Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2023-04-20T18:11:29Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
Estudios in vitro de la Actividad Antitumoral de Complejos de Vanadio con Ácidos Orótico y Glutámico
Estudos in vitro da Atividade Antitumoral de Complexos de Vanádio com Ácidos Órotico e Glutâmico
title In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
spellingShingle In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
Boccato Payolla, Filipe
Carcinoma Hepatocelular
Compostos de Vanádio
Ensaios de Seleção de Medicamentos Antitumorais
Carcinoma, Hepatocellular
Vanadium Compounds
Drug Screening Assays, Antitumor
Carcinoma Hepatocelular
Compuestos de Vanadio
Ensayos de Selección de Medicamentos Antitumorales
Boccato Payolla, Filipe
Carcinoma Hepatocelular
Compostos de Vanádio
Ensaios de Seleção de Medicamentos Antitumorais
Carcinoma, Hepatocellular
Vanadium Compounds
Drug Screening Assays, Antitumor
Carcinoma Hepatocelular
Compuestos de Vanadio
Ensayos de Selección de Medicamentos Antitumorales
title_short In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
title_full In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
title_fullStr In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
title_full_unstemmed In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
title_sort In vitro Studies of Antitumor Activity of Vanadium Complexes with Orotic and Glutamic Acids
author Boccato Payolla, Filipe
author_facet Boccato Payolla, Filipe
Boccato Payolla, Filipe
Andrade Aleixo, Nadia
Resende Nogueira, Flávia Aparecida
Massabni, Antonio Carlos
Andrade Aleixo, Nadia
Resende Nogueira, Flávia Aparecida
Massabni, Antonio Carlos
author_role author
author2 Andrade Aleixo, Nadia
Resende Nogueira, Flávia Aparecida
Massabni, Antonio Carlos
author2_role author
author
author
dc.contributor.author.fl_str_mv Boccato Payolla, Filipe
Andrade Aleixo, Nadia
Resende Nogueira, Flávia Aparecida
Massabni, Antonio Carlos
dc.subject.por.fl_str_mv Carcinoma Hepatocelular
Compostos de Vanádio
Ensaios de Seleção de Medicamentos Antitumorais
Carcinoma, Hepatocellular
Vanadium Compounds
Drug Screening Assays, Antitumor
Carcinoma Hepatocelular
Compuestos de Vanadio
Ensayos de Selección de Medicamentos Antitumorales
topic Carcinoma Hepatocelular
Compostos de Vanádio
Ensaios de Seleção de Medicamentos Antitumorais
Carcinoma, Hepatocellular
Vanadium Compounds
Drug Screening Assays, Antitumor
Carcinoma Hepatocelular
Compuestos de Vanadio
Ensayos de Selección de Medicamentos Antitumorales
description Introduction: Three vanadium complexes with orotic and glutamic acids, in their anion forms, were prepared and their in vitro cytotoxicity toward human lung fibroblasts (MRC-5), human hepatocellular carcinoma (HepG2) and human colorectal adenocarcinoma (Caco-2) are reported. Objective: Describe the synthesis and characterization of new vanadium complexes with orotic and glutamic acids, and test its antitumor activity against HepG2 and Caco-2. Method: The complexes were formulated as VO (oro), VO (α-glu) and VO (γ-glu) based on chemical, thermogravimetric analyses and infrared spectra. Results: Resazurin assay demonstrates its cytotoxicity against the HepG2 and Caco-2 cell lines with the IC50 ranging from 7.90 to 44.56 μmol.L-1. The cytotoxicity profiles indicate that the tumoral lines show more activity than the cells MRC-5, with selectivity indexes ranging from 1.58 to 8.96. Conclusion: The three complexes had better in vitro activity than cisplatin for both normal and cancer cell lines. The IC50 values are two to six times better for the cancer cell lines and five to seven times better for the normal cell lines. This study indicates that the complexes obtained are promising candidates for antitumor drugs.
publishDate 2020
dc.date.none.fl_str_mv 2020-01-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/649
10.32635/2176-9745.RBC.2020v66n1.649
url https://rbc.inca.gov.br/index.php/revista/article/view/649
identifier_str_mv 10.32635/2176-9745.RBC.2020v66n1.649
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/649/533
dc.rights.driver.fl_str_mv Copyright (c) 2020 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 66 No. 1 (2020): Jan./Feb./Mar.; e-04649
Revista Brasileira de Cancerologia; Vol. 66 Núm. 1 (2020): enero/feb./marzo; e-04649
Revista Brasileira de Cancerologia; v. 66 n. 1 (2020): jan./fev.mar.; e-04649
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1822182075488272384
dc.identifier.doi.none.fl_str_mv 10.32635/2176-9745.RBC.2020v66n1.649

Registros relacionados